Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.10 -6.1%	$8.85	$2.20 ▼ $12.78	$249.25M	-0.63	189,263 shs	13,611 shs
ESPR Esperion Therapeutics	$1.17 -2.5%	$0.95	$0.69 ▼ $3.94	$231.89M	0.67	4.86 million shs	2.14 million shs
RENB Renovaro	$0.37 -3.8%	$0.34	$0.27 ▼ $2.10	$62.88M	0.55	1.51 million shs	1.90 million shs
ZYBT Zhengye Biotechnology	$6.34 -13.0%	$8.29	$3.50 ▼ $14.30	$299.03M	N/A	383,365 shs	638,577 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	+11.12%	+13.33%	-11.83%	+98.97%	+84.57%
ESPR Esperion Therapeutics	-0.83%	+3.45%	+53.71%	-20.00%	-58.48%
RENB Renovaro	+10.12%	+21.36%	+13.25%	-52.86%	-73.45%
ZYBT Zhengye Biotechnology	+4.74%	+15.90%	-1.62%	+62.00%	+728,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DBVT DBV Technologies	3.4187 of 5 stars	3.3	5.0	0.0	0.0	3.1	2.5	0.6
ESPR Esperion Therapeutics	4.0767 of 5 stars	3.3	3.0	0.0	3.9	2.8	1.7	0.6
RENB Renovaro	2.3064 of 5 stars	0.0	4.0	0.0	0.0	3.8	3.3	0.6
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.50	Moderate Buy	$14.75	57.69% Upside
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.25	431.91% Upside
RENB Renovaro	0.00	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RENB, ZYBT, ESPR, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/20/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$15.73M	16.29	N/A	N/A	$7.27 per share	1.29
ESPR Esperion Therapeutics	$259.57M	0.90	N/A	N/A	($3.85) per share	-0.31
RENB Renovaro	N/A	N/A	N/A	N/A	$0.52 per share	N/A
ZYBT Zhengye Biotechnology	$189.75M	1.61	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$72.73M	-$4.92	N/A	N/A	N/A	-815.73%	-106.07%	-76.17%	7/29/2025 (Estimated)
ESPR Esperion Therapeutics	-$209.25M	-$0.80	N/A	N/A	N/A	-29.37%	N/A	-10.77%	8/11/2025 (Estimated)
RENB Renovaro	-$80.65M	-$0.77	N/A	∞	N/A	N/A	-61.84%	-48.07%	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest RENB, ZYBT, ESPR, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	2.22	2.22
ESPR Esperion Therapeutics	N/A	1.85	1.37
RENB Renovaro	N/A	0.06	0.08
ZYBT Zhengye Biotechnology	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
ESPR Esperion Therapeutics	47.39%
RENB Renovaro	71.41%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.44%
ESPR Esperion Therapeutics	1.70%
RENB Renovaro	21.72%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	80	27.39 million	20.18 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	195.07 million	Optionable
RENB Renovaro	20	172.12 million	124.24 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

RENB, ZYBT, ESPR, and DBVT Headlines

Recent News About These Companies

Zhengye Biotechnology (NASDAQ:ZYBT) Stock Price Down 6% - Here's Why

June 7, 2025 | americanbankingnews.com

Zhengye Biotechnology (NASDAQ:ZYBT) Trading Down 6% - Time to Sell?

June 7, 2025 | marketbeat.com

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Zhengye Biotechnology (NASDAQ:ZYBT) Trading Up 13.5% - What's Next?

May 14, 2025 | marketbeat.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RENB, ZYBT, ESPR, and DBVT Company Descriptions

DBV Technologies NASDAQ:DBVT

$8.96 -0.74 (-7.59%)

As of 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Esperion Therapeutics NASDAQ:ESPR

$1.17 -0.03 (-2.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.01 (+1.20%)

As of 04:24 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Renovaro NASDAQ:RENB

$0.37 -0.01 (-3.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 -0.01 (-1.72%)

As of 04:29 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Zhengye Biotechnology NASDAQ:ZYBT

$6.34 -0.95 (-13.03%)

As of 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time